Edgestream Partners’s 10x Genomics TXG Stock Holding History

Edgestream Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-58,083	Closed	-$1.23M	–	1141
2026 Q1	$1.23M	Buy	+58,083	New	+$1.16M	0.04%	594
2025 Q4	–	Sell	-75,417	Closed	-$882K	–	1143
2025 Q3	$882K	Buy	+75,417	New	+$983K	0.03%	652
2025 Q1	–	Sell	-190,714	Closed	-$2.74M	–	1080
2024 Q4	$2.74M	Buy	+190,714	New	+$3.01M	0.12%	325
2024 Q3	–	Sell	-11,383	Closed	-$221K	–	1090
2024 Q2	$221K	Sell	11,383 -24,335	-68%	-$637K	0.01%	794
2024 Q1	$1.34M	Buy	+35,718	New	+$1.57M	0.07%	437

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Edgestream Partners's TXG Position: Q2 2026 in Review

Edgestream Partners sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 58,083 shares — an estimated $1.23M sold.

Edgestream Partners first reported a position in TXG in Q1 2024 and held it in 5 quarters. The position peaked at $2.74M in Q4 2024. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Edgestream Partners reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
Edgestream Partners sold 58,083 10x Genomics shares in Q2 2026, an estimated $1.23M.
Edgestream Partners first reported a position in 10x Genomics in Q1 2024 and held it in 5 quarters.
Edgestream Partners's 10x Genomics position peaked at $2.74M in Q4 2024.
391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.